Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7%…
Allogene Therapeutics Conference Call
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for…
The Allogene Therapeutics Fourth Quarter 2025 Conference Call
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment…
TD Cowen 46th Annual Health Care Conference
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.…